Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384664530> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4384664530 abstract "The risk of infections among patients with psoriasis undergoing interleukin (IL)-23 inhibitors (IL-23i) and IL-17 inhibitors (IL-17i) is yet to be exhaustively determined.To assess the risk of infectious complications in patients with psoriasis managed by IL-23i and IL-17i with tumour necrosis factor inhibitors (TNFi) as a comparator.A global cohort study comprised two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL-23i (n = 5272) versus TNFi (n = 5272) and (ii) new users of IL-17i (n = 15,160) versus TNFi (n = 15,160). Study groups were compared regarding the risk of 26 different infections. Propensity score matching was conducted to optimize between-group comparability.Patients under IL-23i had a lower risk of otitis media (HR, 0.66; 95% CI, 0.44-0.97), encephalitis (HR, 0.18; 95% CI, 0.04-0.78), herpes zoster (HZ; HR, 0.58; 95% CI, 0.41-0.82), hepatitis B virus (HBV) reactivation (HR, 0.24; 95% CI, 0.12-0.47), cytomegalovirus (HR, 0.25; 95% CI, 0.07-0.86), influenza (HR, 0.52; 95% CI, 0.38-0.71) and parasitic diseases (HR, 0.78; 95% CI, 0.64-0.95). IL-17i was associated with a decreased risk of pneumonia (HR, 0.76; 95% CI, 0.68-0.85), septicaemia (HR, 0.84; 95% CI, 0.72-0.97), upper respiratory tract infection (HR, 0.84; 95% CI, 0.77-0.92), HZ (HR, 0.79; 95% CI, 0.67-0.92), HBV (HR, 0.59; 95% CI, 0.46-0.76) and hepatitis C virus (HR, 0.71; 95% CI, 0.57-0.88) reactivation, cytomegalovirus (HR, 0.58; 95% CI, 0.36-0.93), Epstein-Barr virus (HR, 0.38; 95% CI, 0.19-0.75), influenza (HR, 0.70; 95% CI, 0.61-0.81) and parasitic diseases (HR, 0.80; 95% CI, 0.72-0.88).Compared with TNFi, IL-23i and IL-17i are associated with decreased risk of several infectious diseases. These agents might be preferred in patients with susceptibility to infections." @default.
- W4384664530 created "2023-07-20" @default.
- W4384664530 creator A5021559096 @default.
- W4384664530 creator A5032799557 @default.
- W4384664530 creator A5070588042 @default.
- W4384664530 creator A5081052338 @default.
- W4384664530 creator A5085831636 @default.
- W4384664530 date "2023-07-19" @default.
- W4384664530 modified "2023-10-17" @default.
- W4384664530 title "Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors – A population‐based study" @default.
- W4384664530 cites W1521666696 @default.
- W4384664530 cites W1988093201 @default.
- W4384664530 cites W2000991311 @default.
- W4384664530 cites W2075994714 @default.
- W4384664530 cites W2076116648 @default.
- W4384664530 cites W2077921764 @default.
- W4384664530 cites W2084740160 @default.
- W4384664530 cites W2109043847 @default.
- W4384664530 cites W2152973730 @default.
- W4384664530 cites W2169071602 @default.
- W4384664530 cites W2524008969 @default.
- W4384664530 cites W2613397542 @default.
- W4384664530 cites W2754072312 @default.
- W4384664530 cites W2789226593 @default.
- W4384664530 cites W2985568363 @default.
- W4384664530 cites W3022405478 @default.
- W4384664530 cites W3028102836 @default.
- W4384664530 cites W3160623885 @default.
- W4384664530 cites W3185691303 @default.
- W4384664530 doi "https://doi.org/10.1111/jdv.19328" @default.
- W4384664530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37466275" @default.
- W4384664530 hasPublicationYear "2023" @default.
- W4384664530 type Work @default.
- W4384664530 citedByCount "0" @default.
- W4384664530 crossrefType "journal-article" @default.
- W4384664530 hasAuthorship W4384664530A5021559096 @default.
- W4384664530 hasAuthorship W4384664530A5032799557 @default.
- W4384664530 hasAuthorship W4384664530A5070588042 @default.
- W4384664530 hasAuthorship W4384664530A5081052338 @default.
- W4384664530 hasAuthorship W4384664530A5085831636 @default.
- W4384664530 hasBestOaLocation W43846645301 @default.
- W4384664530 hasConcept C126322002 @default.
- W4384664530 hasConcept C203014093 @default.
- W4384664530 hasConcept C2908647359 @default.
- W4384664530 hasConcept C50440223 @default.
- W4384664530 hasConcept C71924100 @default.
- W4384664530 hasConcept C90924648 @default.
- W4384664530 hasConcept C99454951 @default.
- W4384664530 hasConceptScore W4384664530C126322002 @default.
- W4384664530 hasConceptScore W4384664530C203014093 @default.
- W4384664530 hasConceptScore W4384664530C2908647359 @default.
- W4384664530 hasConceptScore W4384664530C50440223 @default.
- W4384664530 hasConceptScore W4384664530C71924100 @default.
- W4384664530 hasConceptScore W4384664530C90924648 @default.
- W4384664530 hasConceptScore W4384664530C99454951 @default.
- W4384664530 hasLocation W43846645301 @default.
- W4384664530 hasLocation W43846645302 @default.
- W4384664530 hasOpenAccess W4384664530 @default.
- W4384664530 hasPrimaryLocation W43846645301 @default.
- W4384664530 hasRelatedWork W1966504330 @default.
- W4384664530 hasRelatedWork W1966775726 @default.
- W4384664530 hasRelatedWork W1974041167 @default.
- W4384664530 hasRelatedWork W1979139803 @default.
- W4384664530 hasRelatedWork W2030889776 @default.
- W4384664530 hasRelatedWork W2037631372 @default.
- W4384664530 hasRelatedWork W2070567609 @default.
- W4384664530 hasRelatedWork W2073527559 @default.
- W4384664530 hasRelatedWork W2159000141 @default.
- W4384664530 hasRelatedWork W2391409986 @default.
- W4384664530 isParatext "false" @default.
- W4384664530 isRetracted "false" @default.
- W4384664530 workType "article" @default.